Nivolumab Compared to Docetaxel in Patients With NSCLC

Karen Reckamp, MD, MS

Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).

Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).